Merck: FDA approves use of VAXNEUVANCE

(CercleFinance.com) - The US FDA has approved Merck's VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for the prevention of invasive pneumococcal disease in infants and children ages 6 weeks to 17 years.


The approval follows the FDA's priority review of Merck's supplemental application.

The US Center for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to meet today to discuss and make recommendations on the use of VAXNEUVANCE in pediatric populations.



Copyright (c) 2022 CercleFinance.com. All rights reserved.